501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Granted
U.S. Patent - Cannabis
Drug Detection Device
Cannabix
is developing
Marijuana
Breathalyzer
devices to
give law enforcement and employers
a
tool to
enhance
public safety
Vancouver, British
Columbia -- January
12,
2021 -- InvestorsHub
NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix")
developer of the
Cannabix Marijuana Breathalyzer devices
for law
enforcement and the workplace, announces that
the United
States Patent and
Trademark Office (USPTO)
has
granted patent No.
14/689434
entitled, "Cannabis
Drug Detection Device" to the
Company.
The
Company and its patent attorneys have been pursuing this patent
application since its filing in 2014.
Cannabix
Technologies is
on the
forefront in research and
development to create
point-of-care
breath
testing
technologies for
the
detection of ?9-tetrahydrocannabinol
("THC") - the psychoactive
component of marijuana that causes impairment.
"The
intellectual property protection this THC detection patent covers,
gives Cannabix a broad foundation to build upon in view of the
formidable insights and technical advancements made in the field of
molecular gas analysis at atmospheric pressure that we have
developed since this patent was initially filed in 2014.
Considering the field of breath detection of drugs is in its
infancy, this patent is a useful step in our IP protection
strategy" said Dr. Raj
Attariwala.
In
light of the granting of U.S. patent 14/689434,
the Company undertaken a strategic review of its existing patent
applications and will re-align its portfolio by canceling its
second licence agreement with the University of Florida (UF) in
relation to patent application 16/082,220.
The Company will continue with its original licence agreement with
UF in relation to patent 8,237,118.
As a
requirement under the licence agreement between the Company
and Cannabix
Breathalyzer Inc. (a separate entity)
entered into on June 5th,
2014, Company will issue 5 million common shares to
Cannabix
Breathalyzer Inc. as a final
milestone payment, triggered by the grant of patent
14/689434
by the
USPTO.
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing
accurate,
durable, portable
tools to market to enable
detection of
marijuana-impaired
driving offences on roads at a time when marijuana is becoming
legal in many global jurisdictions. Cannabix is working to develop
drug-testing devices that will detect THC- the psychoactive
component of marijuana that causes intoxication- using breath
samples. In particular, Cannabix is focused on developing breath
testing devices for detection of recent use of THC, in
contrast to urine
testing for THC metabolite that requires an invasive collection and
reflects usage, days or even weeks earlier. The devices will also
be useful for other practical applications such as testing
employees in the workplace where impairment by THC can be
hazardous.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary
Statement Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including:
(i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.